• BAYGN

Bayer's high-dose eye treatment aflibercept shows positive late-stage trial results

Bayer's late-stage trial for aflibercept shows improved vision in patients, suggesting the drug may become a new standard of care for retinal diseases with less frequent injections.

• 8TRA
• BAYGN
• BFSA
• BOSSn
• COP1n
• DE40
• DTEGn
• DTGGe
• DX
• EKTG
• EUR/GBP
• EUR/USD
• EUZG
• EVDG
• EVTG
• GC
• HLE
• HYQGn
• LCO
• MDAXI
• MTXGn
• NA9n
• RHMG
• S92G
• TECDAX
• V1XI
• VOWG_p

Germany stocks mixed at close of trade; DAX down 0.52%

• BAYGN

UBS cuts price target on Bayer on weak outlook

• BAYGN
• BNRGn
• BOSSn
• COKG
• DE40
• DHER
• DX
• ELGG
• ENR1n
• EUR/USD
• EUZG
• EVTG
• GC
• HFGG
• IFXGn
• JENGn
• LCO
• MDAXI
• RRTL
• RWEG
• STM1
• TECDAX
• V1XI

Germany stocks lower at close of trade; DAX down 0.30%

Germany's stocks fell, led by declines in technology and media sectors. Notable gainers included Siemens Energy, while Porsche and RTL faced significant losses.

• BAYGN

Bayer shares plunge on weak Q3, guidance cut

Bayer's Q3 results disappointed, leading to an 11% share drop and a revised EBITDA guidance, highlighting challenges across Pharma and Crop Science divisions.

• AIXGn
• BAYGN
• BC8G
• CL
• CONG
• DE40
• DHER
• EUR/GBP
• EUR/USD
• GC
• GXIG
• HEIG
• HYQGn
• IFXGn
• JENGn
• LCO
• MDAXI
• NA9n
• NDXG
• RHMG
• SMHNn
• SY1G
• TECDAX
• V1XI

Germany stocks higher at close of trade; DAX up 1.00%

Germany's stock market closed higher with the DAX up 1.00%, led by gains in Technology, Retail, and Industrials, while commodities showed mixed results.

• BAYGN

BofA upgrades Bayer on favorable litigation outlook

BofA Securities upgraded Bayer's rating to 'neutral', raising its price target to EUR 31 due to favorable litigation developments and improved business outlook.